Verition Fund Management
IMVT icon

Verition Fund Management’s Immunovant IMVT Stock Holding History

Verition Fund Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-80,794
Closed -$2.05M – 2900
2025
Q4 		$2.05M Sell
80,794
-108,603
-57% -$2.42M 0.01% 1595
2025
Q3 		$3.05M Buy
189,397
+168,243
+795% +$2.72M 0.01% 1622
2025
Q2 		$338K Sell
21,154
-118,163
-85% -$1.79M ﹤0.01% 3149
2025
Q1 		$2.38M Buy
139,317
+59,244
+74% +$1.24M 0.01% 1452
2024
Q4 		$1.98M Buy
+80,073
New +$2.27M 0.01% 1558
2024
Q3 		– Sell
-8,944
Closed -$236K – 3349
2024
Q2 		$236K Sell
8,944
-416
-4% -$11.8K ﹤0.01% 2493
2024
Q1 		$302K Buy
+9,360
New +$341K ﹤0.01% 2296
2023
Q2 		– Sell
-24,910
Closed -$386K – 2370
2023
Q1 		$386K Buy
+24,910
New +$432K 0.01% 1383

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Verition Fund Management's IMVT Position: Q1 2026 in Review

Verition Fund Management sold out of Immunovant (IMVT) in Q1 2026, closing a stake of 80,794 shares — an estimated $2.05M sold.

Verition Fund Management first reported a position in IMVT in Q1 2023 and held it in 8 quarters. The position peaked at $3.05M in Q3 2025. 216 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Verition Fund Management reported no remaining Immunovant position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 80,794 Immunovant shares in Q1 2026, an estimated $2.05M.
  • Verition Fund Management first reported a position in Immunovant in Q1 2023 and held it in 8 quarters.
  • Verition Fund Management's Immunovant position peaked at $3.05M in Q3 2025.
  • 216 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.